Tags |
|
|
Links |
|
|
Advice You - Live Reported From the Stock Exchange: GOOG (-16%) - YHOO (-17%)
So, this will be continued. The expectations are set!
The one dollar and twenty two cents net ea
The one dollar and twenty two cents net ea
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
rnings ($ 1,22) was (way) below the expectations. And so the stock prices (GOOG: $ 393) fell back 9% toda
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
y. Both stocks quote below the level of December when the live reporting began; GOOG (-5% from $ 415) and
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
YHOO (-15% from almost $ 41).
These are however absolute returns. The stocks are setup in a race betwee
These are however absolute returns. The stocks are setup in a race betwee
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
n, but there is no benchmark set for either of them. Lets park that for the next time and we can take the
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
Nasdaq for it (current index: 2301). Also, in order to compare (the competition between) companies you ne
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ed to analyse the difference in focus. (To be elaborated...)
There are two ways in which a growing compa
There are two ways in which a growing compa
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ny can grow even more and there is only one way in which a non-growing company can grow; the first by buy
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ing others and by autonomous growth. Buying other companies is an interesting growth strategy, because th
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
e company can leverage on the growth of the stock price.
For companies that nearly grow cannot use that
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ossibility.
But what happens when you buy your own competitors? This is the topic of this live reporting
But what happens when you buy your own competitors? This is the topic of this live reporting
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
. Most companies have a competitive attitude towards the market, to their environment. But what about the
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
internal market; the market inside the company?
Think about a company that is growing on behalf of buyi
Think about a company that is growing on behalf of buyi
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ng other companies; the competition. Once these companies are absorbed, they will only support the growt
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
h of the main (global) company if these new “satellites” are moved into the same strategic direction. If
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
he companies continue to compete internally the net benefits will be less than the sum of the parts.
If
If
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
you are ambitious to the challenge that the individual parts of your company cooperate rather than compet
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
e (and this holds for both companies that are taken over, as for internal departments), than you should u
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
se different management principles.
This could start for example by withdrawing some freedom the new sat
This could start for example by withdrawing some freedom the new sat
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
ellites have experienced so far, in order to avoid cannibalism and to prosper future synergies.
Hans Boo
Hans Boo
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/23285/adviceyou-Live-Reported-From-the-Stock-Exchange-GOOG-16--YHOO-17.html">Live Reported From the Stock Exchange: GOOG (-16%) - YHOO (-17%)</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/23285/adviceyou-Live-Reported-From-the-Stock-Exchange-GOOG-16--YHOO-17.html]Live Reported From the Stock Exchange: GOOG (-16%) - YHOO (-17%)[/url]
Related Articles:
Give a Little, Gain a Lot: Philanthropic Marketing Yields Big Rewards for Small Businesses
Handling Special Projects for the Project Management Professional
Bookmark it:
|